Genmab A/S (GNMSF PINK) stock market data APIs
$304.916
0(0%)
as of November 17, 2025
Try our APIs with
free plan!
Genmab A/S Financial Data Overview
Price chart is built with
Anychart
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Prev. Close
304.916
Open
304.916
High
304.916
Low
304.916
52 wk Range
170-336.45
Market Cap
18 778 M
P/E Ratio
13.3596
Shares Outstanding
61 567 K
Revenue
3 846 M
EPS
6.46
Beta
0.793
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Genmab A/S (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Genmab A/S data using free add-ons & libraries
Get Genmab A/S Fundamental Data
Genmab A/S Fundamental data includes:
- Net Revenue: 3 846 M
- EBITDA: 1 473 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: 31.81
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Genmab A/S News
New
Edgewise Therapeutics Stock Earns RS Rating Upgrade
Edgewise Therapeutics stock now meets that criteria, with an increase from 80 to 88 Monday. Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or hi...
Ocular Therapeutix Stock Earns 81 RS Rating
Ocular Therapeutix stock is one stock that just reached the mark, now earning a score of 81. Is Ocular Therapeutix Stock A Buy? Ocular Therapeutix stock is currently trading below its 50-day moving average, but rallying with the sector. Continue Reading View Comments
Does Genmab’s Robust Q3 and Upbeat Outlook Reinforce the Bull Case for CPSE:GMAB?
In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...
Syndax Pharmaceuticals Stock Earns RS Rating Upgrade
A Relative Strength Rating upgrade for Syndax Pharmaceuticals shows improving technical performance. Will it continue? Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
